343 related articles for article (PubMed ID: 29318276)
1. Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.
Plevritis SK; Munoz D; Kurian AW; Stout NK; Alagoz O; Near AM; Lee SJ; van den Broek JJ; Huang X; Schechter CB; Sprague BL; Song J; de Koning HJ; Trentham-Dietz A; van Ravesteyn NT; Gangnon R; Chandler Y; Li Y; Xu C; Ergun MA; Huang H; Berry DA; Mandelblatt JS
JAMA; 2018 Jan; 319(2):154-164. PubMed ID: 29318276
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Breast Cancer Mortality in the US-1975 to 2019.
Caswell-Jin JL; Sun LP; Munoz D; Lu Y; Li Y; Huang H; Hampton JM; Song J; Jayasekera J; Schechter C; Alagoz O; Stout NK; Trentham-Dietz A; Lee SJ; Huang X; Mandelblatt JS; Berry DA; Kurian AW; Plevritis SK
JAMA; 2024 Jan; 331(3):233-241. PubMed ID: 38227031
[TBL] [Abstract][Full Text] [Related]
3. A Molecular Subtype-Specific Stochastic Simulation Model of US Breast Cancer Incidence, Survival, and Mortality Trends from 1975 to 2010.
Munoz DF; Xu C; Plevritis SK
Med Decis Making; 2018 Apr; 38(1_suppl):89S-98S. PubMed ID: 29554473
[TBL] [Abstract][Full Text] [Related]
4. Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment.
Munoz DF; Plevritis SK
Med Decis Making; 2018 Apr; 38(1_suppl):32S-43S. PubMed ID: 29554464
[TBL] [Abstract][Full Text] [Related]
5. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.
Munoz D; Near AM; van Ravesteyn NT; Lee SJ; Schechter CB; Alagoz O; Berry DA; Burnside ES; Chang Y; Chisholm G; de Koning HJ; Ali Ergun M; Heijnsdijk EA; Huang H; Stout NK; Sprague BL; Trentham-Dietz A; Mandelblatt JS; Plevritis SK
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25255803
[TBL] [Abstract][Full Text] [Related]
6. Radiation-Induced Breast Cancer Incidence and Mortality From Digital Mammography Screening: A Modeling Study.
Miglioretti DL; Lange J; van den Broek JJ; Lee CI; van Ravesteyn NT; Ritley D; Kerlikowske K; Fenton JJ; Melnikow J; de Koning HJ; Hubbard RA
Ann Intern Med; 2016 Feb; 164(4):205-14. PubMed ID: 26756460
[TBL] [Abstract][Full Text] [Related]
7. Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling.
Mandelblatt JS; Near AM; Miglioretti DL; Munoz D; Sprague BL; Trentham-Dietz A; Gangnon R; Kurian AW; Weedon-Fekjaer H; Cronin KA; Plevritis SK
Med Decis Making; 2018 Apr; 38(1_suppl):9S-23S. PubMed ID: 29554466
[TBL] [Abstract][Full Text] [Related]
8. Mammography screening: A major issue in medicine.
Autier P; Boniol M
Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
[TBL] [Abstract][Full Text] [Related]
9. A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000.
Plevritis SK; Sigal BM; Salzman P; Rosenberg J; Glynn P
J Natl Cancer Inst Monogr; 2006; (36):86-95. PubMed ID: 17032898
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis.
Jatoi I; Chen BE; Anderson WF; Rosenberg PS
J Clin Oncol; 2007 May; 25(13):1683-90. PubMed ID: 17404367
[TBL] [Abstract][Full Text] [Related]
11. Benefits and Harms of Breast Cancer Screening: A Systematic Review.
Myers ER; Moorman P; Gierisch JM; Havrilesky LJ; Grimm LJ; Ghate S; Davidson B; Mongtomery RC; Crowley MJ; McCrory DC; Kendrick A; Sanders GD
JAMA; 2015 Oct; 314(15):1615-34. PubMed ID: 26501537
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
Glass AG; Lacey JV; Carreon JD; Hoover RN
J Natl Cancer Inst; 2007 Aug; 99(15):1152-61. PubMed ID: 17652280
[TBL] [Abstract][Full Text] [Related]
13. A Bayesian Simulation Model for Breast Cancer Screening, Incidence, Treatment, and Mortality.
Huang X; Li Y; Song J; Berry DA
Med Decis Making; 2018 Apr; 38(1_suppl):78S-88S. PubMed ID: 28627297
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model.
Birnbaum J; Gadi VK; Markowitz E; Etzioni R
Ann Intern Med; 2016 Feb; 164(4):236-43. PubMed ID: 26756332
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of breast cancers detected by ultrasound screening in women with negative mammograms.
Bae MS; Han W; Koo HR; Cho N; Chang JM; Yi A; Park IA; Noh DY; Choi WS; Moon WK
Cancer Sci; 2011 Oct; 102(10):1862-7. PubMed ID: 21752153
[TBL] [Abstract][Full Text] [Related]
16. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
17. Quality-of-life effects of screening mammography in Norway.
Zahl PH; Kalager M; Suhrke P; Nord E
Int J Cancer; 2020 Apr; 146(8):2104-2112. PubMed ID: 31254388
[TBL] [Abstract][Full Text] [Related]
18. Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.
Mandelblatt JS; Stout NK; Schechter CB; van den Broek JJ; Miglioretti DL; Krapcho M; Trentham-Dietz A; Munoz D; Lee SJ; Berry DA; van Ravesteyn NT; Alagoz O; Kerlikowske K; Tosteson AN; Near AM; Hoeffken A; Chang Y; Heijnsdijk EA; Chisholm G; Huang X; Huang H; Ergun MA; Gangnon R; Sprague BL; Plevritis S; Feuer E; de Koning HJ; Cronin KA
Ann Intern Med; 2016 Feb; 164(4):215-25. PubMed ID: 26756606
[TBL] [Abstract][Full Text] [Related]
19. Implications of CISNET modeling on number needed to screen and mortality reduction with digital mammography in women 40-49 years old.
Hendrick RE; Helvie MA; Hardesty LA
AJR Am J Roentgenol; 2014 Dec; 203(6):1379-81. PubMed ID: 25415718
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
